Trial
NCT03362294
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Mapi Pharma Ltd.
Collaborators
—
Condition
Primary Progressive Multiple Sclerosis
Intervention
GA Depot 40mg once monthly
Why stopped
The study was terminated early as part of a global realignment of Sponsor's clinical development programs. This decision is not related to any safety concerns regarding the IP.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-23